{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DLL3-expressing+Tumors",
    "query": {
      "condition": "DLL3-expressing Tumors"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T05:12:07.410Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03334487",
      "title": "Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Rovalpituzumab tesirine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-03-15",
      "completion_date": "2018-12-20",
      "has_results": false,
      "last_update_posted_date": "2018-12-26",
      "last_synced_at": "2026-09-11T05:12:07.410Z",
      "location_count": 27,
      "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Fresno, California + 23 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03334487"
    },
    {
      "nct_id": "NCT02709889",
      "title": "Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma",
        "Medullary Thyroid Cancer",
        "Glioblastoma",
        "Large-Cell Neuroendocrine Carcinoma",
        "Neuroendocrine Prostate Cancer",
        "High Grade Gastroenteropancreatic Neuroendocrine Carcinoma",
        "Other Neuroendocrine Carcinoma",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Rovalpituzumab tesirine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 200,
      "start_date": "2016-09-23",
      "completion_date": "2019-08-27",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-09-11T05:12:07.410Z",
      "location_count": 30,
      "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02709889"
    },
    {
      "nct_id": "NCT06814496",
      "title": "Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Medullary Thyroid Cancer",
        "Sinonasal Undifferentiated Carcinoma",
        "Esthesioneuroblastoma",
        "Bladder Cancer",
        "Testicular Cancer",
        "Glioblastoma Multiforme",
        "Cervical Cancer",
        "Large Cell Neuroendocrine Carcinoma of the Lung",
        "Non Small Cell Lung Cancer",
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tarlatamab",
          "type": "DRUG"
        },
        {
          "name": "Concurrent Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Sequential Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-09-08",
      "completion_date": "2030-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-09-11T05:12:07.410Z",
      "location_count": 2,
      "location_summary": "Tucson, Arizona • Seattle, Washington",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06814496"
    },
    {
      "nct_id": "NCT07174583",
      "title": "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small-cell Lung Cancer",
        "Neuroendocrine Carcinomas",
        "Solid Tumor Show to Express DLL3"
      ],
      "interventions": [
        {
          "name": "IDE849",
          "type": "DRUG"
        },
        {
          "name": "durvalumab",
          "type": "DRUG"
        },
        {
          "name": "IDE161",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IDEAYA Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 262,
      "start_date": "2025-10-14",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-09-11T05:12:07.410Z",
      "location_count": 13,
      "location_summary": "Denver, Colorado • Orlando, Florida • Fort Wayne, Indiana + 8 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07174583"
    },
    {
      "nct_id": "NCT07006727",
      "title": "Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Carcinoma",
        "Large Cell Neuroendocrine Carcinoma of the Lung",
        "Neuroendocrine Prostate Cancer",
        "Gastroenteropancreatic Neuroendocrine Carcinoma",
        "Non-prostate Extrapulmonary Neuroendocrine Carcinoma",
        "Cervical Neuroendocrine Carcinoma",
        "Thymic Neuroendocrine Carcinoma",
        "Genitourinary Neuroendocrine Carcinoma",
        "Unknown Primary Neuroendocrine Carcinomas",
        "Merkel Cell Carcinoma",
        "Medullary Thyroid Carcinoma"
      ],
      "interventions": [
        {
          "name": "225Ac-ETN029",
          "type": "DRUG"
        },
        {
          "name": "111In-ETN029",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 123,
      "start_date": "2025-10-16",
      "completion_date": "2031-08-29",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-11T05:12:07.410Z",
      "location_count": 4,
      "location_summary": "Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07006727"
    },
    {
      "nct_id": "NCT06788938",
      "title": "Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "DLL3-expressing Tumors",
        "Advanced Tumors"
      ],
      "interventions": [
        {
          "name": "Tarlatamab treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2025-03-21",
      "completion_date": "2029-04-24",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-09-11T05:12:07.410Z",
      "location_count": 5,
      "location_summary": "Davis, California • Irvine, California • Los Angeles, California + 2 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06788938"
    },
    {
      "nct_id": "NCT04429087",
      "title": "A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3"
      ],
      "interventions": [
        {
          "name": "Obrixtamig - parenteral 1",
          "type": "DRUG"
        },
        {
          "name": "Obrixtamig - parenteral 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2020-07-29",
      "completion_date": "2027-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-11T05:12:07.410Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04429087"
    },
    {
      "nct_id": "NCT05916313",
      "title": "A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "BI 764532",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-01-30",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-11T05:12:07.410Z",
      "location_count": 2,
      "location_summary": "Orange, California • Nashville, Tennessee",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05916313"
    },
    {
      "nct_id": "NCT05652686",
      "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer (SCLC)",
        "Large Cell Neuroendocrine Cancer (LCNEC)",
        "Neuroendocrine Prostate Cancer (NEPC)",
        "Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)",
        "Neuroendocrine Carcinomas (NEC)",
        "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)"
      ],
      "interventions": [
        {
          "name": "Peluntamig (PT217)",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel.",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan (drug)",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phanes Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 203,
      "start_date": "2023-09-05",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-09-11T05:12:07.410Z",
      "location_count": 15,
      "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05652686"
    },
    {
      "nct_id": "NCT07278479",
      "title": "Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Large Cell Neuroendocrine Carcinoma",
        "Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)",
        "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)",
        "Small Cell Lung Cancer (SCLC)",
        "Gastroenteropancreatic NEC (GEP NEC)",
        "NEC of the Bladder",
        "Other DLL3 Expressing epNEC"
      ],
      "interventions": [
        {
          "name": "[212Pb]Pb-MP0712",
          "type": "DRUG"
        },
        {
          "name": "[203Pb]Pb-MP0712",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Molecular Partners AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2026-05-18",
      "completion_date": "2032-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-09-11T05:12:07.410Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Glen Burnie, Maryland • Omaha, Nebraska + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07278479"
    }
  ]
}